Coherus Confirms Filing Plans For Ranibizumab And Bevacizumab

Both Biosimilar Filings Have Experienced Delays

 
• By Dean Rudge
  
FDAEntrance_1200x675
Coherus expects ranibizumab will be filed with the FDA midway through 2021 • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products